Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Chemotherapy (MEDA) With Autologous HSCT in the Treatment of Stage IV Natural Killer/T-Cell Lymphoma: A Multicenter, Prospective Study

NCT02764281 is registered in ClinicalTrials.gov with Xinhua Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT02764281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02764281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Chemotherapy (MEDA) With Autologous HSCT in the Treatment of Stage IV Natural Killer/T-Cell Lymphoma: A Multicenter, Prospective Study
Lead sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2015
Completion date
February 29, 2020
Enrollment
53 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal nk-t-cell lymphoma, nasal type